Medicare GLP-1 Bridge 2026: Covered Drugs, $50 Copay, Key Dates

The Medicare GLP-1 Bridge is a temporary federal program that lets eligible people with Medicare drug coverage get certain GLP-1 medicines for weight management for a $50 copay per one-month supply. It started July 1, 2026, runs through December 31, 2027, and covers Wegovy (injection or tablet), Foundayo, and the Zepbound KwikPen. Nothing else.

That's the short version. The longer version has some fine print, and fine print is where most of the "wait, why did the pharmacy say that?" moments come from. Let's go through it.

What is the Medicare GLP-1 Bridge?

For years the standard Medicare answer to "will Part D pay for my weight-loss medicine?" was no. Part D plans generally can't cover drugs used only for weight loss. Medicare plans could cover some of these medicines for other approved uses, like type 2 diabetes, but not for weight management by itself.

The Bridge works around that. CMS calls it a short-term demonstration, and it runs outside the normal Part D benefit. In practice that means:

• Your Part D plan isn't paying. A single central processor contracted by CMS handles prior authorization, claims and pharmacy payment for 2026. Your plan doesn't carry the cost, and it didn't have to opt in.
• It isn't a new plan. You don't sign up for "the Bridge" the way you'd pick a Part D plan. Your prescriber sends a prescription, the pharmacy runs a claim, and a prior authorization decides whether you qualify.
• It's nationwide. Medicare.gov says it's available in all states and U.S. territories.

Think of it as a side door Medicare built next to Part D, with its own rules on the door.

Which drugs does the Medicare GLP-1 Bridge cover?

There are only three brands, and for one of them only one format counts.

Medicine	What's covered	What's not
Wegovy (semaglutide)	All formulations: weekly injection (the CMS form also lists Wegovy HD) and daily tablet	—
Foundayo (orforglipron)	All formulations (daily tablet)	—
Zepbound (tirzepatide)	KwikPen only (multi-dose pen)	Single-dose vials and single-dose pens
Pen needles	—	Not covered; buy them separately

Some details worth knowing:

• Foundayo was added April 6, 2026, before the program started. CMS says the product list may be updated, so check before assuming anything changes.
• The Zepbound split confuses people. If your prescription is for Zepbound vials, the Bridge won't pay for it. Ask your prescriber whether the KwikPen is an option, but don't switch formats on your own.
• Pen needles aren't included. Multi-dose pens like the KwikPen use separate pen needles, and CMS tells pharmacies not to bill them to the Bridge.
• Coverage is for weight management only. If you take a GLP-1 for type 2 diabetes, that goes through your regular Part D plan.

New to the pills? Our guides to Foundayo and oral vs injectable Wegovy cover the differences.

How much does the Medicare GLP-1 Bridge cost?

The copay is $50 per one-month supply (28 or 30 days, depending on the drug), paid at the pharmacy. That number is simple. What it doesn't do takes a bit more explaining:

• The Part D deductible doesn't apply. You don't have to meet it first.
• The $50 doesn't count toward your Part D deductible or yearly out-of-pocket limit. It won't show up on your Part D Explanation of Benefits either.
• Extra Help can't lower it. There's no low-income subsidy on Bridge claims.
• You can't spread it out with the Medicare Prescription Payment Plan.
• Coupons and discount cards can't be applied, whoever funds them.
• No 60- or 90-day fills. Every fill is one month. Pharmacies can process a vacation fill with a specific override, but there are no overrides for lost or stolen medicine.

The yearly math is easy: 12 fills × $50 = $600 a year. For comparison, the manufacturers' self-pay prices in October 2026 run from $299 to $699 a month for the Zepbound KwikPen depending on dose, and $349 a month for most Wegovy pen doses. At the lowest of those, a year of self-pay is over $3,500. So for someone who qualifies, $50 is a big drop. Those cash prices change, so look them up again before you compare.

One budgeting tip: since the $50 lives outside Part D, it won't help you reach your Part D out-of-pocket cap. Budget for it as a separate line, the same way you'd plan for a full GLP-1 treatment budget.

Key dates for the Medicare GLP-1 Bridge

Date	What happened or happens
April 6, 2026	Foundayo added to the eligible drug list
April 2026	CMS postponed the Part D part of its BALANCE Model for 2027 and extended the Bridge
July 1, 2026	Bridge coverage begins
Oct 15 – Dec 7, 2026	Medicare Open Enrollment for 2027 plans (your plan type affects Bridge eligibility)
December 31, 2027	Bridge scheduled to end; approvals are valid until this date

The approval detail is good news. Medicare.gov says an approved prior authorization stays valid through December 31, 2027, including refills and dose changes, unless you switch to a different GLP-1. So a move from a starting dose to a higher one on the same drug doesn't send you back to square one. Switching from Wegovy to Zepbound does.

What the Bridge does not do

A few points that trip people up:

1. It doesn't cover everyone on Medicare. It's tied to having Medicare drug coverage through certain plan types, plus specific BMI and health criteria. People who already get a GLP-1 through their Part D plan, or who have type 2 diabetes, moderate-to-severe sleep apnea or (noncirrhotic) fatty liver disease, are sent to their Part D plan instead. Our Bridge eligibility checklist goes through each criterion.
2. There's no formal appeals process. CMS says plainly that the Bridge has none. If a request is denied because of wrong or missing information, your prescriber can resubmit the prior authorization form with corrected or new information.
3. It isn't the same as Part D coverage. Some people may qualify for a GLP-1 through their regular plan for a different approved use. We compare the two paths in Medicare Bridge or regular Part D?
4. It isn't permanent. It's a demonstration with an end date.

What happens after December 2027?

Nobody can say yet. CMS extended the Bridge partly to gather data on GLP-1 use and share it with Part D plans ahead of a possible BALANCE Model in Part D. Whether anything replaces the Bridge in 2028, and on what terms, hasn't been announced.

What you can do now is keep good records: the approval letter Medicare mails you, your fill dates, and which product and dose you're on. If the rules change, you and your prescriber will be planning from facts instead of memory. A shot or pill log with refill reminders, like the one in GLPily, makes the "when did I last fill this?" question quick to answer.

Common questions

Do I have to enroll in the Medicare GLP-1 Bridge separately?

No separate plan enrollment. Your prescriber sends a prescription for a covered drug, the pharmacy submits the claim, and your prescriber completes a prior authorization when asked. If approved, you get a letter in the mail confirming coverage under the Bridge.

Does the $50 copay count toward my Part D out-of-pocket maximum?

No. Medicare.gov says it doesn't count toward your yearly Part D deductible or out-of-pocket limit, and it won't appear on your Part D Explanation of Benefits.

Can I use a manufacturer coupon to lower the $50?

No. CMS tells pharmacies that coupons and discount programs can't be applied to Bridge claims, whatever their funding source.

Who do I call with questions about the Bridge?

Call 1-800-MEDICARE (1-800-633-4227; TTY 1-877-486-2048) for eligibility questions, prior authorization status or to report suspected fraud. Your State Health Insurance Assistance Program (SHIP) can also help for free.